[go: up one dir, main page]

UA117470C2 - Заміщені ксантини та способи їх застосування - Google Patents

Заміщені ксантини та способи їх застосування

Info

Publication number
UA117470C2
UA117470C2 UAA201507774A UAA201507774A UA117470C2 UA 117470 C2 UA117470 C2 UA 117470C2 UA A201507774 A UAA201507774 A UA A201507774A UA A201507774 A UAA201507774 A UA A201507774A UA 117470 C2 UA117470 C2 UA 117470C2
Authority
UA
Ukraine
Prior art keywords
methods
substituted xanthines
xanthines
substituted
trpc5
Prior art date
Application number
UAA201507774A
Other languages
English (en)
Inventor
Бертранд Ченард
Ренделл Ґаллашун
Original Assignee
Гайдра Байосаєнсиз, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117470(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Гайдра Байосаєнсиз, Інк. filed Critical Гайдра Байосаєнсиз, Інк.
Publication of UA117470C2 publication Critical patent/UA117470C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описаними є сполуки, композиції та способи інгібування TRPC5 іонного каналу та розладів, пов'язаних з TRPC5.
UAA201507774A 2013-03-15 2014-03-14 Заміщені ксантини та способи їх застосування UA117470C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789724P 2013-03-15 2013-03-15
PCT/US2014/027920 WO2014143799A2 (en) 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof

Publications (1)

Publication Number Publication Date
UA117470C2 true UA117470C2 (uk) 2018-08-10

Family

ID=50680155

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201507774A UA117470C2 (uk) 2013-03-15 2014-03-14 Заміщені ксантини та способи їх застосування

Country Status (32)

Country Link
US (7) US9359359B2 (uk)
EP (1) EP2970303B3 (uk)
JP (1) JP6360149B2 (uk)
KR (1) KR102227629B1 (uk)
CN (2) CN105143229B (uk)
AU (1) AU2014228206C1 (uk)
CA (1) CA2899646C (uk)
CL (1) CL2015002738A1 (uk)
CY (1) CY1119042T1 (uk)
DK (1) DK2970303T6 (uk)
EA (1) EA028815B1 (uk)
ES (1) ES2636835T7 (uk)
HK (1) HK1217329A1 (uk)
HR (1) HRP20170840T4 (uk)
HU (1) HUE033528T4 (uk)
IL (1) IL240216B (uk)
LT (1) LT2970303T (uk)
MX (1) MX370372B (uk)
MY (1) MY189912A (uk)
NZ (1) NZ711718A (uk)
PE (1) PE20151779A1 (uk)
PH (1) PH12015502141B1 (uk)
PL (1) PL2970303T6 (uk)
PT (1) PT2970303T (uk)
RS (1) RS56066B2 (uk)
SG (1) SG11201506479TA (uk)
SI (1) SI2970303T1 (uk)
TW (1) TWI609867B (uk)
UA (1) UA117470C2 (uk)
UY (1) UY35488A (uk)
WO (1) WO2014143799A2 (uk)
ZA (1) ZA201505414B (uk)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
RS56066B2 (sr) 2013-03-15 2018-09-28 Hydra Biosciences Inc Supstituisani ksantini i postupci za njihovu upotrebu
EP3180342B1 (en) * 2014-08-11 2019-06-26 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
WO2016159747A1 (en) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Ethynylxanthines, preparation and use as calcium ion channel modulators
GB2553685B (en) 2015-03-27 2020-06-10 Latvian Inst Organic Synthesis Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis
WO2016159745A1 (en) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Ethynylxanthines, preparation and use for cancer treatment
EP3280417B1 (en) * 2015-04-08 2020-07-29 Lewis and Clark Pharmaceuticals, Inc. Xanthine-substituted alkynyl carbamates/reverse carbamates as a2b antagonists
CN107118586A (zh) * 2016-02-24 2017-09-01 中国科学技术大学 含氮杂环基取代的烯类化合物的用途
GB201702160D0 (en) * 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
US11666577B2 (en) * 2017-02-28 2023-06-06 National Institute Of Biological Sciences, Beijing MLKL inhibitors
CN110573509B (zh) * 2017-02-28 2023-05-26 北京生命科学研究所 Mlkl抑制剂
EP3652176B1 (en) * 2017-07-11 2021-12-15 Boehringer Ingelheim International GmbH Substituted xanthine derivatives
CN118908961A (zh) * 2018-03-05 2024-11-08 金翅雀生物公司 咪唑并二氮杂卓二酮和其使用方法
EP3894409B1 (en) * 2018-12-12 2023-08-23 Boehringer Ingelheim International GmbH Substituted xanthine derivatives
JP7502299B2 (ja) * 2018-12-12 2024-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キサンチン誘導体
CN112979651B (zh) * 2021-04-09 2022-02-01 南京纽邦生物科技有限公司 一种副黄嘌呤的制备方法
CN113354646B (zh) * 2021-07-06 2022-11-15 南开大学 8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用
CN115636831B (zh) * 2022-10-27 2024-11-08 中国药科大学 稠合嘧啶二酮类化合物、其用途以及药物组合物
TW202440582A (zh) 2022-12-20 2024-10-16 德商百靈佳殷格翰國際股份有限公司 ７－（４－氯苯甲基）－１－（３－羥丙基）－３－甲基－８－（３－（三氟甲氧基）－苯氧基）－３，７－二氫－１ｈ －嘌呤－２，６－二酮之製備方法
WO2024153028A1 (zh) * 2023-01-20 2024-07-25 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
WO2024165540A1 (en) 2023-02-06 2024-08-15 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione
WO2024164818A1 (zh) * 2023-02-08 2024-08-15 中国科学院上海药物研究所 黄嘌呤类化合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4304650A1 (de) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JP4191269B2 (ja) 1996-05-17 2008-12-03 興和株式会社 新規なアニリド化合物及びこれを含有する医薬
JPH10318487A (ja) 1997-05-16 1998-12-04 Mitsubishi Gas Chem Co Inc 真空断熱材用ゲッタ
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
DE60024604T2 (de) * 1999-04-09 2006-08-24 Cell Therapeutics, Inc., Seattle Xanthinderivate und analoge als zellsignalisierung inhibitoren
IL153182A0 (en) * 2000-07-04 2003-06-24 Novo Nordisk As Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
RU2003120061A (ru) 2000-12-07 2004-11-27 Си Ви Терапьютикс, Инк. (Us) Замещенные 1,3,5-триазины и пиримидины в качестве повышающих авса-1 соединений против заболевания коронарной артерии или атеросклероза
HU230382B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
PL370207A1 (en) * 2001-11-09 2005-05-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists
AU2003249604B2 (en) * 2003-05-06 2011-06-30 Gilead Sciences, Inc. A2B adenosine receptor antagonists
AU2004291102A1 (en) 2003-11-13 2005-06-02 Board Of Regents, The University Of Texas System Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
EP1841448A2 (en) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
US8143254B2 (en) 2005-02-18 2012-03-27 Cornell Research Foundation, Inc. Methods for modulating ion channels
EP2272848B1 (en) * 2005-08-10 2012-12-26 Glaxosmithkline LLC Xanthine derivatives as selective HM74A agonists
EP1922316B1 (en) 2005-09-06 2010-03-03 GlaxoSmithKline LLC Benzimidazole thiophene compounds as plk modulators
AU2006322349A1 (en) * 2005-12-07 2007-06-14 Ucb Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
WO2007073505A2 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
US20070232673A1 (en) 2006-01-19 2007-10-04 Roth Gregory P 2-Imino-benzimidazoles
WO2007101213A2 (en) 2006-02-28 2007-09-07 Kalypsys, Inc. Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
WO2008011518A2 (en) * 2006-07-19 2008-01-24 Diakine Therapeutics, Inc. Encapsulation system
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
US20120148604A1 (en) 2009-08-20 2012-06-14 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
WO2011114184A1 (en) * 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides of heterocyclic compounds as trpa1 inhibitors
WO2012050641A2 (en) 2010-06-08 2012-04-19 Hydra Biosciences, Inc Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
JP2013023102A (ja) * 2011-07-22 2013-02-04 Panasonic Corp 列車情報提供システム
WO2013023102A1 (en) * 2011-08-09 2013-02-14 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel trpa1
CN103121970B (zh) 2012-12-04 2015-04-29 中国科学院昆明植物研究所 苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用
RS56066B2 (sr) 2013-03-15 2018-09-28 Hydra Biosciences Inc Supstituisani ksantini i postupci za njihovu upotrebu

Also Published As

Publication number Publication date
ES2636835T7 (es) 2018-11-20
US20170305910A1 (en) 2017-10-26
CN105143229A (zh) 2015-12-09
US20160237089A1 (en) 2016-08-18
TWI609867B (zh) 2018-01-01
ES2636835T3 (es) 2017-10-09
US10399982B2 (en) 2019-09-03
US9969736B2 (en) 2018-05-15
HUE033528T2 (hu) 2017-12-28
AU2014228206B2 (en) 2018-05-10
US20140275071A1 (en) 2014-09-18
BR112015021164A8 (pt) 2019-12-03
SI2970303T1 (sl) 2017-08-31
PT2970303T (pt) 2017-06-23
US20250034143A1 (en) 2025-01-30
MX2015011617A (es) 2016-04-25
JP2016513717A (ja) 2016-05-16
JP6360149B2 (ja) 2018-07-18
AU2014228206A1 (en) 2015-09-24
HUE033528T4 (en) 2018-05-02
HK1217329A1 (zh) 2017-01-06
US20230040259A1 (en) 2023-02-09
EP2970303B9 (en) 2017-09-20
PE20151779A1 (es) 2015-11-20
EP2970303B1 (en) 2017-05-10
EA028815B1 (ru) 2018-01-31
NZ711718A (en) 2020-05-29
PL2970303T3 (pl) 2017-08-31
BR112015021164A2 (pt) 2017-07-18
DK2970303T3 (en) 2017-06-26
PH12015502141A1 (en) 2016-01-25
AU2014228206C1 (en) 2018-10-25
PL2970303T6 (pl) 2018-12-31
CN105143229B (zh) 2017-06-30
HRP20170840T4 (hr) 2018-11-16
EP2970303A2 (en) 2016-01-20
US9359359B2 (en) 2016-06-07
IL240216B (en) 2018-11-29
EP2970303B3 (en) 2018-08-01
DK2970303T5 (en) 2018-01-02
WO2014143799A3 (en) 2014-11-06
MX370372B (es) 2019-12-11
MY189912A (en) 2022-03-21
DK2970303T6 (en) 2018-10-08
SG11201506479TA (en) 2015-09-29
WO2014143799A9 (en) 2014-12-24
US20190322667A1 (en) 2019-10-24
WO2014143799A4 (en) 2015-02-12
CN107082782A (zh) 2017-08-22
WO2014143799A2 (en) 2014-09-18
CN107082782B (zh) 2020-03-20
UY35488A (es) 2014-10-31
US20180244674A1 (en) 2018-08-30
CA2899646C (en) 2021-08-31
CY1119042T1 (el) 2018-01-10
TW201533044A (zh) 2015-09-01
LT2970303T (lt) 2017-07-25
PH12015502141B1 (en) 2018-10-12
EA201591615A1 (ru) 2016-05-31
IL240216A0 (en) 2015-09-24
KR102227629B1 (ko) 2021-03-16
US11208409B2 (en) 2021-12-28
CL2015002738A1 (es) 2016-06-10
CA2899646A1 (en) 2014-09-18
KR20150133233A (ko) 2015-11-27
RS56066B2 (sr) 2018-09-28
RS56066B1 (sr) 2017-10-31
HRP20170840T1 (hr) 2017-09-08
ZA201505414B (en) 2016-03-30
US11958854B2 (en) 2024-04-16

Similar Documents

Publication Publication Date Title
UA117470C2 (uk) Заміщені ксантини та способи їх застосування
EA201591420A1 (ru) Гетероарильные соединения и их применение
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2016004927A (es) Composiciones utiles para tratar trastornos relacionados con kit.
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
CR20150524A (es) Compuestos de heteroarilo y sus usos
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
MX2019005192A (es) Compuestos de quinolina selectivamente sustituida.
WO2014152287A3 (en) Substituted xanthines and methods of use thereof
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
IN2015DN00127A (uk)
UY37018A (es) Inhibidores bicíclicos de pad4
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
SG10201902326XA (en) Mk2 inhibitors and uses thereof
MX2018001447A (es) Bloqueadores de canal de ion cargado y metodos para su uso.
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
CL2016000939A1 (es) Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
WO2014146111A3 (en) Analgesic compounds and methods of use